| Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical … JW Eaton, NA Menzies, J Stover, V Cambiano, L Chindelevitch, A Cori, ... The Lancet Global Health 2 (1), e23-e34, 2014 | 244 | 2014 |
| The impact of antiretroviral treatment on the age composition of the HIV epidemic in sub-Saharan Africa JAC Hontelez, SJ de Vlas, R Baltussen, ML Newell, R Bakker, F Tanser, ... Aids 26, S19-S30, 2012 | 198 | 2012 |
| Determinants of the impact of sexually transmitted infection treatment on prevention of HIV infection: a synthesis of evidence from the Mwanza, Rakai, and Masaka intervention … EL Korenromp, RG White, KK Orroth, R Bakker, A Kamali, D Serwadda, ... The Journal of infectious diseases 191 (Supplement_1), S168-S178, 2005 | 183 | 2005 |
| Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study JAC Hontelez, MN Lurie, T Bärnighausen, R Bakker, R Baltussen, ... PLoS medicine 10 (10), e1001534, 2013 | 162 | 2013 |
| Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan … EE Freeman, KK Orroth, RG White, JR Glynn, R Bakker, MC Boily, ... Sexually transmitted infections 83 (suppl 1), i17-i24, 2007 | 150 | 2007 |
| Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when? RG White, JR Glynn, KK Orroth, EE Freeman, R Bakker, HA Weiss, ... Aids 22 (14), 1841-1850, 2008 | 122 | 2008 |
| Ageing with HIV in south africa JAC Hontelez, MN Lurie, ML Newell, R Bakker, F Tanser, T Bärnighausen, ... Aids 25 (13), 1665-1667, 2011 | 114 | 2011 |
| Can population differences explain the contrasting results of the Mwanza, Rakai, and Masaka HIV/sexually transmitted disease intervention trials?: A modeling study RG White, KK Orroth, EL Korenromp, R Bakker, M Wambura, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 37 (4), 1500-1513, 2004 | 110 | 2004 |
| Understanding the differences between contrasting HIV epidemics in east and west Africa: results from a simulation model of the Four Cities Study KK Orroth, EE Freeman, R Bakker, A Buvé, JR Glynn, MC Boily, RG White, ... Sexually transmitted infections 83 (suppl 1), i5-i16, 2007 | 108 | 2007 |
| Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatment LE Coffeng, WA Stolk, A Hoerauf, D Habbema, R Bakker, AD Hopkins, ... PloS one 9 (12), e115886, 2014 | 89 | 2014 |
| Treating curable sexually transmitted infections to prevent HIV in Africa: still an effective control strategy? RG White, KK Orroth, JR Glynn, EE Freeman, R Bakker, JDF Habbema, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 47 (3), 346-353, 2008 | 88 | 2008 |
| Concerted efforts to control or eliminate neglected tropical diseases: how much health will be gained? SJ de Vlas, WA Stolk, EA le Rutte, JAC Hontelez, R Bakker, DJ Blok, ... PLoS neglected tropical diseases 10 (2), e0004386, 2016 | 80 | 2016 |
| HIV dynamics and behaviour change as determinants of the impact of sexually transmitted disease treatment on HIV transmission in the context of the Rakai trial EL Korenromp, R Bakker, SJ Vlas, RH Gray, MJ Wawer, D Serwadda, ... Aids 16 (16), 2209-2218, 2002 | 80 | 2002 |
| The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa JAC Hontelez, SJ De Vlas, F Tanser, R Bakker, T Bärnighausen, ... PloS one 6 (7), e21919, 2011 | 77 | 2011 |
| Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa EE Freeman, RG White, R Bakker, KK Orroth, HA Weiss, A Buvé, ... Vaccine 27 (6), 940-946, 2009 | 68 | 2009 |
| cAMP-mediated effects of ouabain and theophylline on paracellular ion selectivity R Bakker, JA Groot American Journal of Physiology-Gastrointestinal and Liver Physiology 246 (2 …, 1984 | 64 | 1984 |
| Feasibility of controlling hookworm infection through preventive chemotherapy: a simulation study using the individual-based WORMSIM modelling framework LE Coffeng, R Bakker, A Montresor, SJ de Vlas Parasites & vectors 8, 1-16, 2015 | 61 | 2015 |
| Empirical observations underestimate the proportion of human immunodeficiency virus infections attributable to sexually transmitted diseases in the Mwanza and Rakai sexually … KK Orroth, RG White, EL Korenromp, R Bakker, J Changalucha, ... Sexually transmitted diseases 33 (9), 536-544, 2006 | 59 | 2006 |
| Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management … EJ Lenk, WK Redekop, M Luyendijk, C Fitzpatrick, L Niessen, WA Stolk, ... PLoS neglected tropical diseases 12 (3), e0006250, 2018 | 54 | 2018 |
| The socioeconomic benefit to individuals of achieving the 2020 targets for five preventive chemotherapy neglected tropical diseases WK Redekop, EJ Lenk, M Luyendijk, C Fitzpatrick, L Niessen, WA Stolk, ... PLoS neglected tropical diseases 11 (1), e0005289, 2017 | 53 | 2017 |
Sake J. de VlasProfessor, Dept. Public Health, Erasmus MC, Univ. Medical Center Rotterdam, NetherlandsEmail verificata su erasmusmc.nl
